Technavio Announces the Publication of its
Research Report Global Autoimmune and Inflammatory Immunomodulators Market
2016-2020
Technavio recognizes the following companies as the key players in the global autoimmune and inflammatory immunomodulators market: AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, and Pfizer.
Other prominent vendors in the market are: AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Enlivex Therapeutics, Gilead Sciences, Immune Pharmaceuticals, Merck, Mitsubishi Tanabe Pharma, Neovacs, Prometheus Laboratories, Sandoz, Sanofi, Swedish Orphan Biovitrum, Takeda Pharmaceuticals, and UCB.
Commenting on the report, an analyst from Technavio’s team said: “One of latest trends in the market is emergence of oral agents likely to improve patient outcomes. The advent of oral agents in the treatment of rheumatoid arthritis and IBD are expected to have a positive impact on the market growth. For instance, JAK inhibitors such as Xeljanz are expected to become standard therapies in the future, owing to the reduced complications during the administration of drug. Many individuals are reluctant to use injectable medications. Therefore, vendors are increasingly focusing on developing oral agents for the treatment of rheumatoid arthritis. For example, in February 2016, Pfizer received the US FDA approval of Xeljanz XR (tofacitinib citrate), an oral JAK inhibitor, for the treatment of rheumatoid arthritis. As there is an increased need for oral therapies, the new product will substantially fuel the market growth in the future.”
According to the report, one of the primary drivers in the market is strong adoption of TNF-alpha inhibitors and B-cell inhibitors. The physicians prefer to adopt TNF-alpha inhibitors and B-cell inhibitors, owing to their established clinical profiles. For instance, AbbVie's Humira, targeted at autoimmune and other inflammatory indications, reported a worldwide revenue of approximately $14 billion in 2015, indicating an approximate growth of 12% year-on-year (YoY). The strong growth of Humira is attributed to the increasing prescription volume across various therapy areas, including rheumatoid arthritis and IBD. Also, TNF-alpha inhibitors such as Cimzia are posting substantial revenues owing to the increased adoption rates. Cimzia, a treatment for rheumatoid arthritis and Crohn's disease and other autoimmune diseases, reported revenue of $1.2 billion, indicating a YoY growth of 36% (base currencies).
Further, the report states that one major
challenge in the market is discontinuation of drugs under development leading
to substantial loss of revenue. Discontinuation of the drugs under development
or from the market after its launch due to non-satisfactory safety or efficacy
result is a major challenge for the market. Discontinuation in the late stages
of development or from the market will lead to a heavy loss in revenues because
of the high R&D and marketing costs invested by the company.
Discontinuation of rheumatoid arthritis and IBD drugs is high as the drug
target is not properly understood before the drug trial commences. Also, the
drugs are sometimes discontinued at the later stages of the trial as
unacceptable adverse effects appear on the body.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Get discount: https://marketreportscenter.com/request-discount/455986
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Get discount: https://marketreportscenter.com/request-discount/455986
About Autoimmune and Inflammatory Immunomodulators
Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
Technavio’s analysts forecast the global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AbbVie
• Johnson & Johnson
• Amgen
• F. Hoffmann-La Roche
• Pfizer
Other prominent vendors
• AstraZeneca
• Avaxia Biologics
• Biogen Idec
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Eli Lilly
• Enlivex Therapeutics
• Gilead Sciences
• Immune Pharmaceuticals
• Merck
• Mitsubishi Tanabe Pharma
• Neovacs
• Prometheus Laboratories
• Sandoz
• Sanofi
• Swedish Orphan Biovitrum
• Takeda Pharmaceuticals
• UCB
Market driver
• Development of novel therapies using innovative technologies.
• For a full, detailed list, view our report
Market challenge
• Discontinuation of drugs under development leading to substantial loss in revenue.
• For a full, detailed list, view our report
Market trend
• Advent of biosimilars expected to improve the treatment rates.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Immunomodulators are the drugs that help to regulate the immune system. These drugs either stimulate the weak immune systems or moderate the overactive immune systems. Though many drugs are available in the market, there still exists a huge unmet need in the autoimmune and inflammatory immunomodulators market as there are no medicines that provide complete cure to some diseases such as rheumatoid arthritis, ulcerative colitis, and Crohn’s disease.
Technavio’s analysts forecast the global autoimmune and inflammatory immunomodulators market to grow at a CAGR of 7.01% during the period 2016-2020.
Covered in this report
The report covers the present scenario and the growth prospects of the global autoimmune and inflammatory immunomodulators market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of the marketed drugs during the forecast period.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Autoimmune and Inflammatory Immunomodulators Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• AbbVie
• Johnson & Johnson
• Amgen
• F. Hoffmann-La Roche
• Pfizer
Other prominent vendors
• AstraZeneca
• Avaxia Biologics
• Biogen Idec
• Bristol-Myers Squibb
• Boehringer Ingelheim
• Eli Lilly
• Enlivex Therapeutics
• Gilead Sciences
• Immune Pharmaceuticals
• Merck
• Mitsubishi Tanabe Pharma
• Neovacs
• Prometheus Laboratories
• Sandoz
• Sanofi
• Swedish Orphan Biovitrum
• Takeda Pharmaceuticals
• UCB
Market driver
• Development of novel therapies using innovative technologies.
• For a full, detailed list, view our report
Market challenge
• Discontinuation of drugs under development leading to substantial loss in revenue.
• For a full, detailed list, view our report
Market trend
• Advent of biosimilars expected to improve the treatment rates.
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
Table
of content: https://marketreportscenter.com/reports/455986/global-autoimmune-and-inflammatory-immunomodulators-market-2016-2020#toc
About Us:
Market
Reports Center is an e-commerce platform obliging the needs of knowledge
workers, experts, professionals who are subject to market research information
for their work, or to make strategic business decisions. Market Reports
Center’s team consistently works to update and extend our existing repository
of market research reports by partnering with new publishers and adding their
studies to our website.
Contact us for more details:
Sam Collins
Market
Reports Center
Phone No: 1-646-883-3044 (US)
Email: info@marketreportscenter.com
No comments:
Post a Comment